Koyfin Home > Directory > Health Care > Arena Pharmaceuticals > EBITDA

Arena Pharmaceuticals EBITDA Chart (ARNA)

Arena Pharmaceuticals annual/quarterly EBITDA from 2000 to 2018. EBITDA stands for earnings before interest, taxes, depreciation and amortization. EBITDA is one indicator of a company's financial performance and is used as a proxy for the earning potential of a business, although doing so can have drawbacks. EBITDA strips out the cost of debt capital and its tax effects by adding back interest and taxes to earnings.
  • Arena Pharmaceuticals EBITDA for the quarter ending December 12, 2018 was $-44m a 31.55% decrease of -14m year over year
  • Arena Pharmaceuticals EBITDA for the last 12 months ending December 12, 2018 was $-141m a 38.82% decrease of -55m year over year
  • Arena Pharmaceuticals Annual EBITDA for 2018 was $-141m a 46.29% decrease of -65m from 2017
  • Arena Pharmaceuticals Annual EBITDA for 2017 was $-76m a 107.72% decrease of -82m from 2016
  • Arena Pharmaceuticals Annual EBITDA for 2016 was $6m a 1,720.53% increase of 101m from 2015
Other Income Statement Metrics:
  • Arena Pharmaceuticals Net Income for the quarter ending December 12, 2018 was $69m a 146.52% increase of 101m year over year
  • Arena Pharmaceuticals Total Revenue for the quarter ending September 09, 2018 was $4m a -330.00% decrease of -12m year over year
View Chart On Koyfin

Quarterly ARNA EBITDA Data

12/2018$-44m
09/2018$-35m
06/2018$-32m
03/2018$-30m
12/2017$-13m
09/2017$-21m
06/2017$-22m
03/2017$-20m
09/2016$-7m
06/2016$-18m

Annual ARNA EBITDA Data

2018$-141m
2017$-76m
2016$6m
2015$-95m
2014$-96m
2013$-15m
2012$-47m
2011$-68m
2010$-84m
2009$-121m